Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAS-205 in Duchenne Muscular Dystrophy
NCT02246478Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pizuglanstat in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Incidence of Adverse Events at 14 days. Started Sep 2014; status: completed.
02
Drugs
pizuglanstat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02246478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246478.